Mark Samir Salem

Mark Salem practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Mark Salem's NPI, 1821356254, was assigned on April 23, 2012. Mark Salem graduated from University of Miami, Miller School of Medicine in 2012. Mark Salem holds California license A127236.

Mark Salem's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Mark Salem's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Salem practices. Vendor and product names are available with a free account.

Gastroenterology is Mark Salem's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Mark Salem is board certified in gastroenterology by the American Board of Internal Medicine. Dmand AI has Mark Salem's licenses on file in 2 states: California and Pennsylvania.

Dmand AI lists acid reflux and chronic inflammatory bowel disease (IBD) among the conditions Mark Salem treats.

CMS data shows 34 Medicare services from Mark Salem across 1 procedure code in 2024, all of them office visits, for 26 Medicare patients. Medicare paid $2,738 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 26 Medicare patients who saw Mark Salem in 2024. The largest group is 65 to 74, with 12 patients. 73% of them have high cholesterol, and 69% have high blood pressure. 46% are also on Medicaid. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Mark Salem's median patient age at 33, with 46% women.

In 2024, Mark Salem wrote 180 Medicare Part D claims for 29 patients. 44% of them were for generic drugs. CMS names the drug for 86 of them, across 5 drugs with 11 or more claims each, at $735,590 in total drug cost. In 2023, CMS named 41 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Mark Salem for performance year 2024, reported through an alternative payment model (APM). Mark Salem accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Mark Salem as offering telehealth.

Dmand AI links 5 papers to Mark Salem, published from 2012 to 2017. Mark Salem's most frequent co-authors are Jason Ken Hou, MD, Richa Shukla and Maria Teresa Abreu, MD.

Dmand AI links Mark Salem to 1 clinical trial. Conditions studied include Crohn Disease and Inflammatory Bowel Diseases.

CMS Open Payments shows 39 general payments to Mark Salem from 12 drug and device companies from 2017 to 2025. Grants make up the largest share, 88% of the total. Pfizer Inc. paid the most, $40,077.

Mark Salem graduated from University of Miami, Miller School of Medicine in 2012.

Mark Salem is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.